After two months, Novo Nordisk and HIMS part ways
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
Latest
Preserving muscle: GLP1s with Bimagrumab
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
Novo Nordisk patent protections lapse in Canada
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
A challenge to Eli Lilly's Tirzepatide patent
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
Amylin, with and without GLP1: Eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
Ozempic is not likely to directly enlarge the male appendage.
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
Eli Lilly's big Summer 2025 update
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
Semaglutide vs Tirzepatide (Clinical trial)
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
Roche and Carmot's GLP1 pipeline
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
A new risk: Kidney Cancer
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
GLP1s vs. Addiction, a quick review
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.
An update on Retatrutide (May 2025)
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
category:benefits
GLP1s lower inflammation, Psoriasis, AND increase fertility?
We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.
politics
GLP1s and Tariffs, the story so far
We take a look at the various movements in GLP1 policy by the Trump administration, so far.
drug:wegovy
Wegovy in pill form is coming
Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
drug:nimacimab
Boosting Tirzepatide with Nimacimab
Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.
company:eli-lilly
Eli Lilly suing GLP1 compounders & related companies
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
company:pfizer
Pfizer ends development of oral GLP1 Danuglipron
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
drug:mounjaro
Mounjaro's India launch
Eli Lilly's Mounjaro launches in India
category:news
Oral pill Orforglipron delivers stellar results in Phase 3 Trial
Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!
politics
Trump revokes planned Medicare/Medicaid coverage for GLP1s
Trump administration revokes the planned Medicare Part D coverage for anti-obesity GLP1 drugs.
politics
2025 Trump Tariffs on Pharmaceutical Imports
Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.
Once a year GLP1? Exploring Semaglutide implants
GLP1 implants that are administered once or twice a year and deliver consistent Semaglutide, powered by Vivani Medical's NanoPortal technology.
category:news
Hims pivots to branded Tirzepatide, generic Liraglutide
Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.